entity

MFSD2A (SLC59A1)

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about MFSD2A (SLC59A1): its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1Connections
1Hypotheses
1Analyses
1Outgoing
0Incoming
0Experiments
1Debates

No AI portrait yet

Outgoing (1)

TargetRelationTypeStr
neuropharmacologypromoted: MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Resolving Prodrugsdisease0.55

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CN 0.551 neuropharmacology What determines blood-brain barrier pene

Mentioning Analyses (1)

Scientific analyses that reference this entity

What determines blood-brain barrier penetration kinetics for specialized pro-res

neuropharmacology | 2026-04-13 | 2 hypotheses Top: 0.551

Experiments (0)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found

Debates (1)

Multi-agent debates referencing this entity

The debate highlighted BBB penetration as a major hurdle for SPM therapeutics bu

closed · Rounds: 4 · Score: 0.66 · 2026-04-13

Related Research

Hypotheses and analyses mentioning MFSD2A (SLC59A1) in their description or question text

No additional research found